sebia Labordiagnostische Systeme GmbH

Sebia is a world-leading company in the field of In-Vitro Diagnostics, specializing in the development and distribution of devices and reagents for the early detection and monitoring of various diseases. These primarily include Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathies, Autoimmune Diseases, and rare pathologies[3][5].

The mission of Sebia is to provide powerful tools that translate the processes in a patient's body into a readable and interpretable language – the so-called "new language of life". This enables a better understanding, diagnosis, and treatment of chronic and metabolic diseases[5].

Sebia offers a wide range of Capillary Electrophoresis Devices and Reagents used for the analysis of proteins in biological samples. A highlight is the Sebia Lean Service, which enhances laboratory efficiency through modular and scalable solutions[3][4].

Sebia places great importance on Quality and Compliance. The company is certified according to ISO 13485:2016 and meets the requirements of MDSAP. A strict code of conduct and a comprehensive quality management system ensure ethical business practices and high product quality[2].

With a global network in over 120 countries and 14 subsidiaries, Sebia is present worldwide and continuously strives to strengthen its international influence to better serve customers[1].

Sebia is also committed to Research and Development to develop innovative diagnostic solutions and improve medical care[5].

• 1 - https://www.sebia.com/en-us/sebia/worldwide-presence-en-us/
• 2 - https://www.sebia.com/de/sebia/qualitat-compliance-de/
• 3 - https://www.sebia.com/en-us/
• 4 - https://www.sebia.com/de/losungen/sebia-lean-service/
• 5 - https://www.sebia.com/en-us/sebia/company-overview-en-us/